Themis Medicare Ltd
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]
- Market Cap ₹ 2,646 Cr.
- Current Price ₹ 288
- High / Low ₹ 317 / 154
- Stock P/E 50.0
- Book Value ₹ 44.8
- Dividend Yield 0.17 %
- ROCE 13.5 %
- ROE 11.8 %
- Face Value ₹ 1.00
Pros
Cons
- Earnings include an other income of Rs.23.1 Cr.
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
174 | 195 | 202 | 232 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 382 | 420 | |
157 | 171 | 184 | 194 | 184 | 184 | 181 | 166 | 181 | 299 | 287 | 330 | 357 | |
Operating Profit | 17 | 24 | 18 | 38 | 33 | 25 | 2 | 36 | 49 | 96 | 67 | 52 | 64 |
OPM % | 10% | 12% | 9% | 16% | 15% | 12% | 1% | 18% | 21% | 24% | 19% | 13% | 15% |
3 | 5 | 13 | 3 | 4 | 6 | 5 | 12 | 13 | 18 | 25 | 24 | 23 | |
Interest | 15 | 16 | 15 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 9 | 10 |
Depreciation | 9 | 9 | 11 | 12 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 | 11 |
Profit before tax | -4 | 4 | 5 | 17 | 18 | 11 | -13 | 27 | 41 | 95 | 73 | 53 | 66 |
Tax % | 56% | 32% | -20% | 11% | 9% | 1% | -15% | 8% | 14% | 23% | 22% | 19% | |
-6 | 3 | 6 | 16 | 16 | 11 | -11 | 25 | 36 | 73 | 57 | 44 | 53 | |
EPS in Rs | -0.79 | 0.32 | 0.73 | 1.91 | 1.77 | 1.23 | -1.17 | 2.70 | 3.88 | 7.92 | 6.18 | 4.73 | 5.75 |
Dividend Payout % | -11% | 28% | 25% | 9% | 0% | 0% | 0% | 6% | 11% | 6% | 8% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 16% |
3 Years: | 18% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 41% |
3 Years: | 6% |
TTM: | 3% |
Stock Price CAGR | |
---|---|
10 Years: | 33% |
5 Years: | 64% |
3 Years: | 47% |
1 Year: | 87% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 18% |
3 Years: | 18% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 43 | 48 | 51 | 66 | 143 | 160 | 149 | 174 | 209 | 278 | 330 | 368 | 403 |
155 | 148 | 140 | 128 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 96 | 81 | |
65 | 79 | 77 | 73 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 93 | 109 | |
Total Liabilities | 272 | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 602 |
124 | 121 | 122 | 117 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 168 | 174 | |
CWIP | 11 | 12 | 4 | 6 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 | 3 |
Investments | 4 | 4 | 5 | 6 | 23 | 24 | 27 | 35 | 45 | 56 | 70 | 89 | 99 |
134 | 147 | 146 | 146 | 133 | 153 | 162 | 191 | 191 | 225 | 279 | 307 | 326 | |
Total Assets | 272 | 284 | 277 | 275 | 289 | 305 | 314 | 350 | 371 | 428 | 514 | 566 | 602 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 8 | 19 | 26 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | 22 | |
-5 | -7 | -6 | -7 | -4 | -0 | -4 | -5 | -16 | -16 | -24 | -16 | |
29 | 2 | -18 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | -9 | |
Net Cash Flow | 29 | 4 | -5 | 5 | -0 | -1 | -3 | 2 | 16 | 1 | -8 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 68 | 74 | 82 | 75 | 81 | 120 | 145 | 186 | 123 | 93 | 149 | 170 |
Inventory Days | 246 | 280 | 246 | 243 | 250 | 253 | 287 | 315 | 272 | 150 | 213 | 188 |
Days Payable | 232 | 240 | 237 | 145 | 163 | 156 | 187 | 171 | 143 | 79 | 123 | 126 |
Cash Conversion Cycle | 82 | 114 | 91 | 172 | 168 | 216 | 244 | 330 | 251 | 164 | 239 | 232 |
Working Capital Days | 87 | 81 | 78 | 64 | 74 | 131 | 132 | 176 | 152 | 124 | 176 | 180 |
ROCE % | 5% | 10% | 9% | 15% | 13% | 10% | -1% | 15% | 18% | 30% | 20% | 14% |
Documents
Announcements
-
Announcement Under Regulation 30 (LODR)
1d - Received Rs. 4.18 crores tax demand from Income Tax Department.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Amalgamation of Gujarat Themis Biosyn with Themis Medicare approved.
-
Board Meeting Outcome for Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015, ('Listing Regulations') - Outcome Of Board Meeting
2d - Board approves termination of agreement and amalgamation scheme.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Oct
- Announcement under Regulation 30 (LODR)-Investor Presentation 25 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Oct 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT REC
-
Nov 2022Transcript PPT
Business Segments[1]
A) Hospital Business - Critical Care Division, Intensive Care Division, Institution Business, Exports. Hospital Business is a major growth driver. Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospital/doctor’s coverage.